ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.297,66
0,01%
Dow Jones
39.898,92
0,07%
Euro vs US Dollar
1,08714
0,03%
Bitcoin
67.234,65
3,06%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Avenue Therapeutics Inc (ATXI)

  7. Avenue Therapeutics Inc (ATXI) News

ATXI

Avenue Therapeutics (ATXI)

Avenue Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ATXI
DatumZeitQuelleÜberschriftSymbolFirma
16/05/202414h30GlobeNewswire Inc.Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
15/05/202415h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
15/05/202414h30GlobeNewswire Inc.Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
13/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
10/05/202422h53Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ATXIAvenue Therapeutics Inc
10/05/202422h52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATXIAvenue Therapeutics Inc
29/04/202414h00GlobeNewswire Inc.Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
24/04/202413h30GlobeNewswire Inc.Avenue Therapeutics Announces Reverse Stock SplitNASDAQ:ATXIAvenue Therapeutics Inc
25/03/202413h30GlobeNewswire Inc.Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024NASDAQ:ATXIAvenue Therapeutics Inc
18/03/202421h05GlobeNewswire Inc.Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:ATXIAvenue Therapeutics Inc
15/03/202413h15GlobeNewswire Inc.Avenue Therapeutics Receives Positive Listing Determination from NasdaqNASDAQ:ATXIAvenue Therapeutics Inc
11/03/202413h00GlobeNewswire Inc.Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
08/03/202422h31Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
08/03/202422h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
22/02/202414h30GlobeNewswire Inc.Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyNASDAQ:ATXIAvenue Therapeutics Inc
02/02/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATXIAvenue Therapeutics Inc
29/01/202414h00Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:ATXIAvenue Therapeutics Inc
24/01/202422h11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATXIAvenue Therapeutics Inc
17/01/202423h05Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:ATXIAvenue Therapeutics Inc
12/01/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
11/01/202414h00GlobeNewswire Inc.Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceNASDAQ:ATXIAvenue Therapeutics Inc
08/01/202423h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATXIAvenue Therapeutics Inc
05/01/202415h15GlobeNewswire Inc.Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsNASDAQ:ATXIAvenue Therapeutics Inc
04/01/202414h30GlobeNewswire Inc.Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolNASDAQ:ATXIAvenue Therapeutics Inc
02/01/202414h30GlobeNewswire Inc.Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)NASDAQ:ATXIAvenue Therapeutics Inc
13/12/202322h03Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ATXIAvenue Therapeutics Inc
13/12/202322h02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
01/12/202314h30GlobeNewswire Inc.Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingNASDAQ:ATXIAvenue Therapeutics Inc
28/11/202322h05Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ATXIAvenue Therapeutics Inc
28/11/202322h01Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATXIAvenue Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATXI

Kürzlich von Ihnen besucht

TG
TUI1
Tui
CCOM
US100
US Tech 100
USOTC
BASFY
BASF (QX)
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
DBI
DAX
DAX
USOTC
RHHBY
Roche (QX)
NYSE
MCD
McDonalds
AMEX
XLV
Health Care Select Sector
TG
BAYN
Bayer
TG
RHM
Rheinmetall
FX
EURGBP
Euro vs Sterling
FX
EURUSD
Euro vs US Dollar
NASDAQ
NVDA
NVIDIA
NYSE
NKE
Nike
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten